Retour sur lavenir.net
   SOFINA 244.600 € (-1,92 %)     ARGENX SE 855.200 € (+17,12 %)     PROXIMUS 6.165 € (-1,83 %)     TUBIZE-FIN 184.800 € (+1,43 %)     NEXTENSA 46.100 € (+0,22 %)     AZELIS GROUP 11.910 € (-1,33 %)     ASCENCIO 51.700 € (-0,77 %)     ABO GROUP 3.800 € (-3,06 %)     AEDIFICA 67.150 € (-1,18 %)     IMMOBEL 20.800 € (-0,95 %)     ACCENTIS 0.027 € (0,00 %)     BPOST 1.346 € (-3,17 %)     DECEUNINCK 2.255 € (-0,22 %)     DEME GROUP 169.800 € (+1,31 %)     XIOR 26.800 € (-1,65 %)     TINC 11.280 € (+0,53 %)     ENERGYVISION 15.340 € (+0,92 %)     ATENOR 1.285 € (-4,10 %)     LOTUS BAKERIES 12 380.000 € (+0,49 %)     NYXOAH 1.402 € (0,00 %)     UCB 215.400 € (+1,46 %)     SOLVAC NOM(RETAIL) 85.000 € (0,00 %)     FLUXYS BELGIUM D 20.300 € (-0,98 %)     CAMPINE 196.000 € (-1,51 %)     ELIA GROUP 127.400 € (-0,93 %)     GBL 73.300 € (-2,07 %)     KINEPOLIS GROUP 41.300 € (-0,36 %)     ONTEX GROUP 2.435 € (-1,81 %)     VGP 78.700 € (-1,38 %)     AGEAS 73.200 € (+0,07 %)     AB INBEV 67.020 € (-2,33 %)     AGFA-GEVAERT 0.379 € (-0,26 %)     GIMV 43.750 € (-0,46 %)     MONTEA 64.800 € (-1,37 %)     CMB.TECH 15.080 € (+1,34 %)     WERELDHAVE BELGIUM 53.000 € (+1,15 %)     ONWARD MEDICAL 2.320 € (-2,32 %)     TESSENDERLO 20.850 € (-1,18 %)     VIOHALCO 17.840 € (-0,22 %)     ORANGE BELGIUM 22.000 € (-0,45 %)     MELEXIS 72.000 € (+1,77 %)     SHURGARD 23.750 € (-1,86 %)     CIE BOIS SAUVAGE 296.000 € (-1,00 %)     CARE PROPERTY INV. 12.160 € (-0,65 %)     JENSEN-GROUP 70.000 € (-1,96 %)     RECTICEL 12.660 € (-0,47 %)     KBC ANCORA 92.600 € (-0,32 %)     WDP 20.940 € (-1,51 %)     QUESTFOR GR-PRICAF 2.995 € (-1,74 %)     TITAN S.A. 51.100 € (+0,10 %)     SIPEF 100.400 € (-2,14 %)     CENERGY 23.380 € (+0,86 %)     IBA 15.900 € (-0,87 %)     CELYAD ONCOLOGY 0.279 € (+4,10 %)     BARCO 7.925 € (-0,19 %)     COLRUYT 38.060 € (-0,73 %)     UMICORE 23.940 € (+2,13 %)     FAGRON 22.450 € (-0,22 %)     D'IETEREN GROUP 173.600 € (-0,52 %)     SYENSQO 81.800 € (-0,79 %)  
   PHILIPS KON 23.300 € (-1,52 %)     LATECOERE 0.015 € (-0,67 %)     MAGNUM 16.460 € (-3,24 %)     INNATE PHARMA 1.806 € (-2,80 %)     RELX 29.080 € (-2,35 %)     BIOPHYTIS 0.095 € (+24,18 %)     TRIODOS BANK 35.200 € (+0,43 %)     BE SEMICONDUCTOR 237.800 € (+1,84 %)     HERMES INTL 1 550.000 € (-1,65 %)     ASML HOLDING 1 621.200 € (+2,63 %)     QUADIENT 12.220 € (-0,97 %)     ADYEN 1 031.400 € (-2,84 %)     SAFRAN 361.100 € (+0,17 %)     PUBLICIS GROUPE SA 100.600 € (-1,18 %)     AHOLD DEL 31.660 € (-2,28 %)     KERING 257.100 € (-4,26 %)     SIDETRADE 197.000 € (-1,30 %)     AIR FRANCE -KLM 12.005 € (-1,60 %)     SOCIETE GENERALE 82.140 € (-0,27 %)     DANONE 65.240 € (-2,97 %)     EIFFAGE 119.900 € (-0,75 %)     ELIOR GROUP 2.100 € (-2,33 %)     STMICROELECTRONICS 49.060 € (+5,15 %)     RISING STONE 50.700 € (0,00 %)     BNP PARIBAS ACT.A 111.140 € (-0,86 %)     FONCIERE INEA 32.500 € (-0,31 %)     VERIMATRIX 0.339 € (+16,90 %)     BUREAU VERITAS 27.630 € (+0,22 %)     SHELL PLC 39.150 € (+0,46 %)     WINAMP GROUP 0.394 € (-0,13 %)     LLAMA GROUP 0.394 € (-0,13 %)     WORLDLINE 12.214 € (-4,29 %)     KERLINK 1.060 € (+2,91 %)     NEXITY 7.465 € (0,00 %)     L'OREAL 370.000 € (-2,50 %)     EUROFINS SCIENT. 70.000 € (-0,62 %)     ALTAREA 99.000 € (-0,60 %)     MAUNA KEA TECH 0.160 € (+8,25 %)     UMG 14.805 € (-0,94 %)     KLARSEN 1.380 € (+2,99 %)     CASINO GUICHARD 0.194 € (+0,52 %)     ADVICENNE 1.730 € (+3,47 %)     KAUFMAN ET BROAD 25.050 € (0,00 %)     NN GROUP 78.560 € (-0,25 %)     PIERRE VACANCES 1.862 € (-0,11 %)     FORVIA 9.132 € (-1,02 %)     KPN KON 4.049 € (-0,64 %)     ACCOR 46.070 € (-1,26 %)     LVMH 446.000 € (-2,71 %)     NOVACYT 0.545 € (+5,21 %)     SANOFI 76.660 € (+1,51 %)     Vusion 132.300 € (+1,07 %)     ALSTOM 16.075 € (-0,96 %)     BENETEAU 6.150 € (-0,65 %)     SARTORIUS STED BIO 181.600 € (-2,10 %)     HAL TRUST 162.800 € (-1,21 %)     DSM FIRMENICH AG 87.500 € (-2,56 %)     GTT 206.800 € (+0,19 %)     ARAMIS GROUP 4.135 € (-4,06 %)     ABN AMRO BANK N.V. 41.870 € (+1,06 %)  
News Réglementées
17/08/2026 16:05

Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk's New York

EQS-News: Mavrix / Key word(s): Miscellaneous/Miscellaneous
Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk's New York

17.08.2026 / 16:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Mavrix, the global data acquisition and research execution company, used its Platinum Sponsorship of The Quirk's Event New York 2026 to advance a clear view on the changing research landscape: as artificial intelligence makes data generation and analysis faster and more accessible, the ability to reach, verify and engage the right real people is becoming more valuable, not less.

Mavrix Makes the Case for Trusted Human Evidence in the AI Era at Quirk’s New York

Held July 29–30 at the Javits Center, Mavrix participated in two featured sessions, first with Delineate and then with Boston Consulting Group (BCG) and Knit.

In 'Free Data, Worthless Data: What's Actually Left Worth Paying For,' Mavrix and Delineate examined how AI is automating survey creation, coding, summarization, analysis and reporting. The session's central argument was that as routine production becomes easier to automate, value shifts toward evidence that is harder to replicate: proprietary and timely signals, verified human participation, hard-to-reach audiences and judgment about what matters.

"AI gives our industry extraordinary capabilities," said Glen Collins, EVP, Global Commercial Group at Mavrix. "But AI cannot fix speaking to the wrong people. If the human evidence underneath is weak, technology simply allows us to analyze weak evidence faster and with greater confidence. Better human evidence in means better intelligence out."

Mavrix also described verification as a Human Evidence Chain: Reach, Qualify, Verify, Engage and Defend. The objective is not more checks, but evidence that can withstand scrutiny when findings are challenged.

On Day 2 of the Quirk's conference, Mavrix joined BCG and Knit to discuss Qual-at-Scale, examining how AI moderation, video and analysis can enable richer participant conversations at greater speed and scale. For Mavrix, a key implication is that participant eligibility alone is no longer enough. Richer tasks require people who are relevant, articulate, engaged, authentic and ready to contribute.

Across both sessions, Mavrix's message converged around three factors: speed, quality and AI. Speed makes research timely enough to influence a decision. Quality makes the evidence worth acting on. AI helps surface patterns at previously impractical scale.

Mavrix also reinforced a broader principle: the audience should determine the recruitment method, not the other way around. Online, telephone, specialist communities, face-to-face and mixed methods may all be appropriate depending on the audience and market.

For more information, visit www.mavrixdata.com

Media Contact
media@mavrixdata.com 

Mavrix Logo

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/mavrix-makes-the-case-for-trusted-human-evidence-in-the-ai-era-at-quirks-new-york-302852901.html

rt.gif?NewsItemId=EN27414&Transmission_Id=202608171000PR_NEWS_EURO_ND__EN27414&DateId=20260817


17.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2384254  17.08.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière